Magenta Therapeutics Stock

MGTA

US55910K1088

Market Closed - Nasdaq 23:00:00 11/09/2026 +03			5-day change	1st Jan Change
106.20 ^USD	+2.83%		-4.24%	+848.76%

11/09/23	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
11/09/23	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI

Valuation : Magenta Therapeutics

Market Cap	42.24M 36.4M 34.46M 31.24M 58.6M 4.04B 58.9M 409M 157M 2.05B 159M 155M 6.49B	P/E 2021	-3.42x	P/E 2022	-0.31x
Enterprise Value	-39.84M -34.32M -32.5M -29.46M -55.26M -3.81B -55.54M -386M -148M -1.94B -150M -146M -6.12B	EV / Sales 2021	-	EV / Sales 2022	-
Free-Float	-	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Latest news : Magenta Therapeutics

11/09/23	Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index	CI
11/09/23	Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	CI
03/08/23	Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index	CI
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index	CI
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index	CI
23/06/23	Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index	CI
19/05/23	Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer	CI
15/05/23	Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
03/05/23	Dianthus Therapeutics, Inc., Magenta Therapeutics, Inc. - M&A Call
03/05/23	Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.	CI
06/04/23	Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc	CI
28/02/23	HC Wainwright Initiates Magenta Therapeutics at Neutral	MT

More news

Analysts' recommendations : Magenta Therapeutics

28/02/23	HC Wainwright Initiates Magenta Therapeutics at Neutral	MT
26/01/23	BTIG Downgrades Magenta Therapeutics to Neutral From Buy	MT
26/01/23	Cowen Downgrades Magenta Therapeutics to Market Perform From Outperform	MT
26/01/23	Wedbush Downgrades Magenta Therapeutics to Neutral From Outperform on MGTA-117 Safety Issues, Lowers Price Targe to $1 From $3	MT
21/12/22	BTIG Lowers Price Target on Magenta Therapeutics to $3 From $6, Maintains Buy Rating	MT

More recommendations

Press Releases : Magenta Therapeutics

11/09/23	Adrenoleukodystrophy Clinical Trials, and Key Companies\|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others	AQ
07/08/23	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	BU
04/05/23	MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA	BU
03/05/23	MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
03/05/23	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement	AQ

More press releases

Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.

Employees

Sector

More about the company

Quotes

Date	Price	Change
11/09/26	$106.20	+2.83%
10/09/26	$103.28	-3.51%
09/09/26	$107.04	-1.92%
08/09/26	$109.13	+0.95%
04/09/26	$108.10	+0.23%

Delayed Quote Nasdaq

More quotes

5 years	5.14		135.84
10 years	5.14		336

	2021	2022
Net sales	-	-
Net income	-71.14M -61.29M -58.03M -52.6M -98.68M -6.8B -99.18M -689M -265M -3.46B -267M -261M -10.93B	-76.46M -65.88M -62.38M -56.54M -106M -7.3B -107M -741M -285M -3.72B -287M -281M -11.74B
Net Debt	-177M -152M -144M -131M -245M -16.9B -247M -1.71B -659M -8.6B -664M -650M -27.17B	-82.08M -70.72M -66.96M -60.69M -114M -7.84B -114M -795M -306M -3.99B -308M -301M -12.61B

Magenta Therapeutics Stock

Stocks

MGTA

US55910K1088

Valuation : Magenta Therapeutics

Chart: Magenta Therapeutics

Latest news : Magenta Therapeutics

Analysts' recommendations : Magenta Therapeutics

Press Releases : Magenta Therapeutics

Quotes and Performance

Price Extremes

Financials

Company Profile

Quotes

Markets		Quality
Nasdaq	MGTA	Delayed
Deutsche Boerse AG	3MT	Delayed

1 day	+2.83%
Current month	+848.76%
Current year	+848.76%